In:
Frontiers in Immunology, Frontiers Media SA, Vol. 13 ( 2022-5-26)
Abstract:
Chimeric antigen receptor (CAR) T cells have been successfully used in the therapy of B cell leukemia and lymphoma, but still have many challenges in their use for treating T cell malignancies, such as the lack of unique tumor antigens, their limitation of T cell expansion, and the need for third party donors or genome editing. Therefore, we need to find novel targets for CAR T cell therapy to overcome these challenges. Here, we found that both adult T-cell leukemia/lymphoma (ATLL) patients and ATLL cells had increased CCR8 expression but did not express CD7. Moreover, targeting CCR8 in T cells did not impair T cell expansion in vitro . Importantly, anti-CCR8 CAR T cells exhibited antitumor effects on ATLL- and other CCR8-expressing T-ALL cells in vitro and in vivo , and prolonged the survival of ATLL and Jurkat tumor-bearing mouse models. In conclusion, these collective results show that anti-CCR8 CAR T cells possess strong antitumor activity and represent a promising therapeutic approach for ATLL and CCR8 + tumors.
Type of Medium:
Online Resource
ISSN:
1664-3224
DOI:
10.3389/fimmu.2022.808347
DOI:
10.3389/fimmu.2022.808347.s001
DOI:
10.3389/fimmu.2022.808347.s002
DOI:
10.3389/fimmu.2022.808347.s003
DOI:
10.3389/fimmu.2022.808347.s004
DOI:
10.3389/fimmu.2022.808347.s005
DOI:
10.3389/fimmu.2022.808347.s006
DOI:
10.3389/fimmu.2022.808347.s007
Language:
Unknown
Publisher:
Frontiers Media SA
Publication Date:
2022
detail.hit.zdb_id:
2606827-8
Permalink